PhytoHealth Corporation (4108) Stock Overview

PhytoHealth Corporation researches and develops, manufactures, and sells pharmaceutical drugs, cosmetics, Class B medicines, and dietary supplements in Taiwan. The company operates in three segments: Pharmaceutical Drugs and Dietary Supplement, Medical Diagnostic Products, and Precision Medical Equipment. The Pharmaceutical Drugs and Dietary Supplement segment manufactures and sells Chinese medicine and new pharmaceutical products. The Medical Diagnostic Products segment develops and sells smart medical imaging diagnostic products device. The Precision Medical Equipment segment engages in the research and development, manufacturing, and sale of ultrasonic probes. The company's products under development include PHN031, which has completed Phase II clinical trials for the treatment of osteoporosis; and PHN033, which has completed Phase II clinical trials for the treatment of diabetic nephropathy. It is also developing PHN016 that is in Phase II clinical trials for the treatment of cancer; and PHN017 for the treatment of severe infection-induced cytokine storm and is in phase I trial. In addition, the company offers PG2 Lyophilized injection for the treatment of cancer related fatigue; and capsules. PhytoHealth Corporation was incorporated in 1998 and is based in Taipei, Taiwan.